Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
News Release Digital Asset Direct

Vitaquest International Joins Council for Responsible Nutrition as Voting Member

Vitaquest

Vitaquest International, an industry-leading product development and commercialization partner in nutraceuticals and functional foods announced today that it has been accepted as a Voting Member at the Council for Responsible Nutrition (CRN) (Washington, DC). The 50-year-old CRN is a leading standards-promoting and advocacy association representing producers of dietary supplements, functional foods and health-promoting ingredients. According to Patrick Brueggman, Chief Executive Officer of Vitaquest, the move to join CRN reinforces recognition by the company of the impact and value the trade association has on advancing the scientific, quality and ethical standards of the nutraceuticals and functional foods industries. “The Council for Responsible Nutrition is a leader in focusing attention and supporting the issues that are critical to the advancement of our industry. Over their 50-year history, they have advocated for best practices in clinical science, manufacturing, marketing, quality control and safety,” he said. “We are delighted to become a voting member of CRN as we share its commitment to advancing all these best practices and to building trust with consumers as we provide finished products that support their health. We’re looking forward to engaging with other member companies of CRN and adding Vitaquest’s voice to a dialogue that looks to move our industry ahead,” he said. Brueggman has been appointed to the Council for Responsible Nutrition Board of Directors. Manufacturing Quality Supplements and Functional Foods for Over 45 years Vitaquest has been delivering innovation in consumer products since 1977. Over the last 45-plus years the company has established itself as one of the premier product development and manufacturing companies in the nutraceutical and functional foods business. It has grown as a result of successful collaborations with customers, its continual investment in the facilities and capabilities needed to support customers, and the company’s ability to anticipate the requirements of their markets. This is a full-service offering that includes formulation assistance, manufacturing, packaging, warehousing and fulfillment. Today, the company produces more than 4,000 custom formulas each year, serving more than 500 brands in 40 countries. On the quality front, Vitaquest offers its TotalQ™ Commitment to Quality, an initiative that draws on the company's activities in a broad range of functions and disciplines including raw material sourcing, ingredient integrity testing, product design, internal QA systems and final product Assurance. The company also offers VQ Solutions, a turnkey warehousing and fulfillment option for customers that starts from our manufacturing floor and ends at their customer’s location – getting products faster to market, reducing shipping costs and providing storage in a fully-certified storage facility. Says Brueggman, “At Vitaquest, we like to say that we can help our customers deliver what’s next in the health and well-being market. We feel that CRN has their eye on the future of our industry and we look forward to working closely with them to improve what comes next”. “The Council for Responsible Nutrition is a leader in focusing attention and supporting the issues that are critical to the advancement of our industry. Over their 50-year history, they have advocated for best practices in clinical science, manufacturing, marketing, quality control and safety. We are delighted to become a voting member of CRN as we share its commitment to advancing all these best practices and to building trust with consumers as we provide finished products that support their health." -- Patrick Brueggman, CEO of Vitaquest. About Vitaquest International Headquartered in West Caldwell, NJ USA, Vitaquest International is an industry-leading development and commercialization partner for consumer products featuring a broad array of innovative solutions in nutraceutical and functional foods. A leader in the design and development of new, standards-based quality initiatives, a comprehensive commitment to quality – called TotalQ™ – is at the core of Vitaquest as a company. With over 45 years of history, Vitaquest has the market insight, global reach and scale of operations to support emerging and existing consumer brands from the idea to the store shelf – with flawless execution in every phase. Contact Details Resource Advantage Dan Green dgreen@resourceadvantage.com

January 30, 2023 09:00 AM Eastern Standard Time

Image

Central Health Sues Ascension for Failing to Live Up to its Contractual Commitments to Care for Travis County Residents with Low Income

Central Health

Central Health sued Ascension Texas (Ascension), formerly known as Seton Healthcare Family, Tuesday for failing to meet its contractual obligations to provide healthcare for Travis County residents with low income. Several hours after Central Health filed its original petition, Ascension filed suit. “We were out of options,” said Mike Geeslin, President & CEO of Central Health, in regard to Central Health’s petition. “Ascension’s persistent failures to honor its contractual commitments left Central Health with no choice but to file a lawsuit to hold Ascension accountable for not providing adequate, equitable healthcare services for people with low income in Travis County. Their practices have caused real harm to the people we serve.” History: City of Austin, Ascension, and Central Health When it was formed in 2004, Central Health inherited the City of Austin’s relationship with Ascension, which was intended to help fulfill Central Health’s mission to care for Travis County residents with low income. As part of that relationship, Ascension operated University Medical Center Brackenridge Hospital and provided healthcare to Travis County’s safety-net population. After Central Health was formed, it acquired the property on which University Medical Center Brackenridge sat; however, pursuant to a lease, Ascension continued to operate that hospital. Unlike other major urban hospital districts in Texas, Central Health has never operated a public hospital. Instead, it relies on Ascension to keep its long-standing contractual commitments to provide hospital and most specialty care to Travis County’s safety-net population. Long-Standing Contractual Relationship Between Central Health and Ascension Between 2004 and 2013, Central Health and Ascension worked together under a Safety Net Agreement to provide healthcare services to Travis County residents with low income. In 2013, Ascension recommitted to its contractual obligation to care for Travis County residents with low income, and it agreed that going forward, it would provide at least “the current levels of healthcare services,” including hospital and specialty care, that it had been providing. These renewed contractual commitments applied to patients enrolled in Central Health’s Medical Access Program (MAP), which is a health coverage program for uninsured Travis County residents with low income (MAP Patients), and to certain patients who are “financially indigent” or “medically indigent,” as defined by Ascension’s Charity Care Policy (Charity Care Patients). Per the 2013 Safety Net Agreement between Ascension and Central Health, Ascension continued to receive compensation for providing care and participated in projects eligible for Medicaid 1115 Transformation Waiver funding. Ascension also received additional public funding. In addition, Ascension was permitted to affiliate with the Central Health-supported Dell Medical School at The University of Texas at Austin, as part of the development of the new teaching and safety-net hospital—Dell Seton Medical Center at The University of Texas at Austin. In operating Dell Seton Medical Center, Ascension is standing in for Central Health, as the local hospital district, in providing healthcare services to Travis County residents with low income. Thus, Ascension’s right to operate the hospital is conditioned on Ascension fulfilling its contractional obligations to Central Health. Ascension Caring for Fewer Patients Ascension’s own data shows that it has failed to provide healthcare services to MAP Patients and Charity Care Patients at the agreed-upon 2013 levels. In the 2022 contract year, Ascension served approximately 8,000 fewer patients in the hospital compared with the 2013 contract year, reflecting a roughly 21% reduction. Patient encounters also dropped. In the 2022 contract year there were approximately 31,000 fewer patient hospital encounters (including inpatient services, outpatient services, and emergency room visits) compared with the 2013 contract year, reflecting a roughly 33% reduction. Central Health alleges that Ascension’s failures apply not only to the overall levels of healthcare services, but also to numerous specialty areas, including general surgery, mammography, oncology radiation therapy, orthopedics, otolaryngology, podiatry, plastic surgery, pulmonology, and rheumatology. “While Ascension substantially benefited from its contracts with Central Health, it failed to meet its commitments to us,” said Dr. Charles Bell, Central Health Board of Managers Chair. “Over the years, Ascension has cared for fewer and fewer patients and that’s neither acceptable nor contractually allowable. We reached a point where our only option was taking Ascension to court. We hoped it would never come to this.” “We believe Ascension’s failure to provide agreed-upon healthcare cannot be explained by a lack of need in our community or by mere happenstance,” said Casey Dobson of Scott Douglass & McConnico, the law firm representing Central Health. “We believe it stems from Ascension reducing, capping, and eliminating services for MAP Patients and Charity Care Patients. The unfortunate reality is that many Travis County residents with low income who needed critical care from Ascension did not receive that care.” The End of the Line: Pursuing Equity, Declarations, and Damages Central Health and Ascension have been talking and negotiating for years to try and rectify the situation. Last week, Central Health and Ascension reached the end of their contractually required alternative dispute resolution efforts. When those efforts failed, Central Health had no other option but to seek court intervention. The Lawsuit In its lawsuit, Central Health asserts breach-of-contract claims against Ascension for the following things: Failing to provide agreed-upon healthcare services to low-income Travis County residents, both overall and in relation to several specialty areas; Failing to provide healthcare services to MAP Patients and Charity Care Patients on a nondiscriminatory basis; Improperly billing Charity Care Patients for healthcare services; and Not providing required reports that Central Health needs to monitor, on behalf of Travis County residents, Ascension’s compliance with performance standards. Additionally, because Ascension’s failures are so consequential, Central Health seeks a judicial declaration that would entitle it to terminate agreements with Ascension and trigger Central Health’s option to purchase Dell Seton Medical Center. “This option is not something we wanted to pursue,” said Dr. Bell. “But we have to do what is necessary to ensure that, in the future, this safety-net hospital will deliver the level and quality of care that Travis County residents with low income need and deserve.” Central Health also seeks other declarations to resolve ongoing disagreements with and relating to Ascension. A copy of the complete Original Petition is available here. ### About Central Health Central Health is the local hospital district that connects one in seven Travis County residents with low income to quality health care. We work with a network of partners to eliminate health disparities and reach our vision of Travis County becoming a model healthy community. Contact Details Ted Burton, Chief Communications Officer Central Health +1 512-797-8200 Ted.Burton@centralhealth.net

January 27, 2023 12:00 PM Central Standard Time

Creo Medical Group currently worth "about £100mln", says Proactive research analyst

Creo Medical Group PLC

Proactive research analyst John Savin speaks to Thomas Warner about his latest research note on Creo Medical Group. He gives his take on how the group is currently performing, suggesting that it is currently worth "about £100mln", and looks ahead to what investors can expect from it over the coming years. Contact Details Proactive UK Ltd Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

January 27, 2023 03:00 AM Eastern Standard Time

Video

News Release

Freedom Holdings Signs Definitive Agreement with MEDcann Industries, Inc.

FREEDOM HLDG INC.

MCapMediaWire -- Freedom Holdings, Inc. (OTC: FHLD ) (“FHLD” or the "Company”), is pleased to announce that it has entered into a Definitive Agreement that will change the control and operations of the Company to MEDcann Industries, Inc. MEDcann is going to modify the forward direction of Freedom to include topical and organic natural Marijuana plant-based products (OTC) “over the counter” entering the Cannabis health care products market in which the Company management believes will boost shareholder value. Freedom Holdings management will bring the companies platforms to a new level to be current with all SEC, OTC and FINRA requirements, publishing its 2022-year end Information and Statements to bring the company current and re-structuring the company with a productive reorganization. The will allow the Company to negotiate with private companies in the Cannabis industry specifically looking for beverage, cosmetics, vitamin, and medicinal companies to acquire and or joint venture with. Under the terms of the agreement, MEDcann is to purchase 40,000,000 restricted shares from the Company for $50,000.00 (.00125 per share) representing the 80% ownership of the Company and Brian Kistler shall resign all Officer/Director positions only to serve as an advisor for a period of 2 years to insure a smooth transition and John Vivian, CEO of MEDcann shall simultaneously be appointed as the Chairman and CEO of Freedom and MEDcann as the parent company shall assume the debt and ongoing operational costs of Freedom All financial disclosures are to be brought current The Closing of the conditions as outlined, Freedom has become a majority owned subsidiary of MEDcann with operations of MEDcann Industries to be transferred into Freedom for future development. About MEDcann Industries, Inc. MEDcann Industries, Inc. was founded in Februsry 2020 to create and develop a high-quality worldwide Distribution, Research and Manufacturing Facility. Investigating the resources, we found many different types of products and plan to be one of the competitive manufactures and marketers. We intend to manufacture and assemble everything from Medicine, Cosmetic to Health treatment products and drinks. For more information regarding MEDcann please visit https://MEDcannindustries.com/ Press Release Contact: Brian Kistler CEO Freedom Holdings, Inc. 260-490-9990 John Vivian CEO MEDcann Industries, Inc 813-699-4098 Safe Harbor Statement This press release contains statements, which may constitute forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief, or current expectations of the Company, members of its management, and assumptions on which such statements are based. We caution prospective investors that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties and that actual results may differ materially from those contemplated by such forward-looking statements. Contact Details Freedom Holdings, Inc. Brian Kistler +1 260-490-9990 MEDcann Industries, Inc John Vivian +1 813-699-4098

January 26, 2023 01:28 PM Eastern Standard Time

CeCors Finalizes Terms with VetComm to Enter the Multi-Billion Dollar Veteran Benefits Industry

CeCors, Inc.

McapMediaWire - CECORS, INC. (OTC: CEOS ) ("CeCors" or the "Company"), is pleased to provide corporate highlights from the final quarter of fiscal 2022 and an update to the earlier press release dated December 19, 2022, regarding initial negotiations with VetComm Corp. CeCors and VetComm founder, Kate Monroe have agreed in principle to terms as part of the planned 100 percent purchase of VetComm Corp. VetComm Corp. is a veteran's education, and benefits company focused on assisting the over 14 million United States veterans that qualify for underutilized annual benefits and owed compensation, resulting in estimated Billions of dollars of unclaimed benefits every month in the United States. Users of VetComm can file claims for free, with no medical or service records required. VetComm also focuses resources to support and donate to Veteran Charities. VetComm's goal for 2023 is to help 1 million veterans get rated, offering support packages leading to benefits with costs ranging from $247 to $997, generating potential revenues for VetComm between $247 million and $997 million annually. As part of the initially agreed-upon terms of the acquisition, CeCors will issue a combination of unregistered, restricted preferred and common shares. In addition, each of Sukhinder Kalsi, Director and CFO and Amar Bhatal, President, Secretary and Director, will assign half of their Series A Preferred Shares to VetComm founder Kate Monroe as part of the proposed acquisition terms. Management of the Company continues to be focused on limiting dilution and bringing value to shareholders using CeCors current capital structure. Concurrent with closing, Kate Monroe will step in as CEO of CeCors, Inc., and VetComm will operate as a wholly-owned subsidiary. Operations of the controlled subsidiary PsyKey, Inc. will continue to run in parallel. "Now that we have come to a mutual agreement on the terms of the acquisition, we can focus on closing and consolidating our efforts moving forward. We have worked diligently to reach terms agreeable to all parties and expect to close the transaction in Q1 2023. The more we learned about VetComm as part of our due diligence process, the more we understood VetComm's vast potential for growth. Kate is determined to enroll 1 million veterans into the VetComm platform this fiscal year (2023), potentially putting billions of dollars into the pockets of deserving veterans who have put their lives on the line for their country." commented Mr. Sukhinder Kalsi, CeCors' Chief Financial Officer. Mr. Kalsi added, "Kate is the most determined and motivated individual I've ever encountered. Being a marine corps veteran, she has real insight into the daily challenges veterans face due to a lack of financial and mental health resources. With the current uncertainty in the global economy, VetComm can be an indispensable service partner for all vets seeking benefits." "I'm very excited to have come to terms on the acquisition of VetComm. We have an opportunity to get our message out to every veteran who is entitled to unused benefits and compensation. The idea of being involved with a public company only enhances our platform to get our message out to the over 14 million veterans who are entitled to compensation. With our existing high-level political and celebrity backing, we're confident we will hit our goal of enrolling 1 million veterans this year," concluded Kate Monroe. Year in Review for CeCors, Inc. 2022 Milestones The Company has worked diligently over the past year to acquire its initial revenue-generating operations, and OTCMarkets has recently updated our online profile to denote our exit from Shell Status. This milestone was in part achieved as a result of the successful launch of our first retail-ready product offering, PsyKey Functional Mushroom Infused Coffee. The launch saw both consumer support and major corporate interest leading to the fulfillment of substantial purchase orders. Continuing with management's goal of steady corporate growth and wanting to help create inclusivity and ease of access to mental health support, the Company also recently completed the development of its Telemental Health App PsyKey Live. The App is currently being beta tested with real-world scenarios and expanded to allow for additional capabilities. Building a strong medical, scientific, and management team also continues to be a priority for the Company and was complemented by the 2022 additions of John Gustin as head of Global Business Development; Dr. Michael J. McCarthy as an appointee to our Scientific Advisory Board; and Dr. Shahiem Hartley to our Medical Advisory Board. The addition of Dr. Hartley will help the Company build a mental health support and education platform, while the additions of John Gustin and Dr. McCarthy provide a conduit into the scientific world and the ability for the Company to adequately develop and introduce scientific advancements and patented technologies to the market. On behalf of the entire CeCors and PsyKey team, we would like to express our deepest gratitude to our amazing shareholders for their patience and support this past year. We are excited about what 2023 has in store for the Company, and we look forward to providing regular updates as we continue. For further information: Publicly traded company (OTC: CEOS) Website: www.psykeyworld.com E-mail: info@psykeyworld.com Follow us on Twitter: https://twitter.com/PsyKeyworld Forward-Looking Statements: Safe Harbour Statement - In addition to historical information, this press release may contain statements that constitute forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release include the intent, belief, or expectations of the Company and members of its management team with respect to the Company's future business operations and the assumptions upon which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance, and involve risks and uncertainties and that actual results may differ materially from those contemplated by such forward-looking statements. Factors that could cause these differences include, but are not limited to, failure to complete anticipated sales under negotiations, lack of revenue growth, client discontinuances, failure to realize improvements in performance, efficiency, and profitability, and adverse developments with respect to litigation or increased litigation costs, the operation or performance of the Company's business units or the market price of its common stock. Additional factors that could cause actual results to differ materially from those contemplated within this press release can also be found on the Company's website. The Company disclaims any responsibility to update any forward- looking statements. Contact Details Sukhinderpaul Kalsi info@psykeyworld.com Company Website https://psykeyworld.com/

January 26, 2023 09:45 AM Eastern Standard Time

2022 Was A Year Of Growth, Funding, And Positive Results For BioRestorative Therapies

BioRestorative Therapies, Inc.

By Faith Ashmore, Benzinga BioRestorative Therapies Inc. (NASDAQ: BRTX) (“BioRestorative”) may have had a successful year of novel drug development. The company is engaged in developing therapeutic products using cell and tissue protocols, primarily with adult stem cells, for large multi-billion dollar markets that are underserved and affect millions of Americans, like chronic lower back pain and metabolic disorders. BioRestorative currently has two major programs that are being evaluated for a variety of chronic diseases and pain. Their novel drug BRTX-100 is an autologous stem cell product; the cells are harvested, cultured and then injected directly into the patient’s body. BioRestorative’s other product — ThermoStem® — has shown promising results in preclinical models for the treatment of obesity and related metabolic diseases. In December, BioRestorative was awarded a Small Business Innovation Research (SBIR) grant. This grant was given for the development and evaluation of the company’s ThermoStem program for developing a therapeutic to treat polycystic ovary syndrome (PCOS). Previously, the company was granted a Small Business Technology Transfer (STTR) grant for Phase 1 development of BRTX-100 to explore the therapeutic effects of PEG-peptide hydrogel-encapsulated hypoxic bone marrow stem cells. It’s rare that a company of its size has received two government grants, validating its technology and potential application. The company entered into an agreement with Regenexx, LLC, providing BioRestorative with the exclusive worldwide commercial rights of the intellectual property that is underlying some key principles of BRTX-100. Currently, BRTX-100 is in a Phase 2 trial with approximately 15 sites in the U.S. This exclusive arrangement should provide value to BRTX and or a commercial partner in potential later-stage development transactions. BRTX-100 began Phase 2 trials in February, defined as a prospective, randomized, double-blinded controlled study to evaluate the efficacy and safety of BRTX from a single injected dose. One of the company’s significant developments in 2022 was the completion of a cGMP manufacturing facility with an ISO 7-certified clean room. This facility was completed in April and was instrumental in progressing the company forward to meet the needs of Phase 2 clinical trials for chronic lumbar disc disease. Throughout the year, BioRestorative participated in several high-profile conferences. The company presented at H.C. Wainwright Bioconnect, Roth Inaugural Healthcare Conference and Dawson James Securities Conference, to name a few. BioRestorative was also granted a patent application for their ThermoStem program in Japan, which demonstrates the company’s potential for global application of their therapeutic products. BioRestorative and other companies like Lineage Cell Therapeutics Inc (NYSE: LCTX), Brainstorm Cell Therapeutics Inc (NASDAQ: BCLI), Vericel Corp (NASDAQ: VCEL) and large cap pharma as well such as Novo Nordisk (NYSE: NVO) and Pfizer Inc. (NYSE: PFE) are leading the charge towards a new era of medical advancement. As biotech companies become increasingly successful at providing therapeutic solutions, it will be interesting to see how technology and innovation leads to higher quality of life for patients who have previously been left with little or no solutions. To learn more about BioRestorative, visit its website. This article was originally published on Benzinga here. BioRestorative Therapies was founded by scientists and researchers committed to developing stem cell therapies to address unmet needs in patients with highly prevalent conditions.Our advances in stem cell biology and delivery protocols harbor great promise in conditioning our bodies’ own regenerative potential to treat major diseases more effectively than current interventions.Today, BioRestorative is actively developing programs that aim to dramatically increase quality of care for both (i) chronic back pain caused by disc degeneration, as well as (ii) metabolic disorders including obesity and diabetes. This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Investor Relations ir@biorestorative.com Company Website https://www.biorestorative.com/

January 26, 2023 08:30 AM Eastern Standard Time

1606 Corp Now Trading under Ticker CBDW, Management Announces First Acquisition

1606 Corp

McapMediaWire -- 1606 Corp (OTC: CBDW ), an acquisition-based CBD product distribution company, announced that the company has successfully started trading on the OTC Market under the Ticker Symbol of CBDW. 1606 Corp’s S-1 registration statement became effective on January 22, 2022 and began trading on the OTC Market on January 17th, 2023. CBDW is a ticker symbol that embodies the business model of 1606 Corp and highlights management's goal to build a product-driven CBD-Wellness company. CBD.Inc and 1606 Corp. look to accumulate a diverse portfolio of CBD products and companies nationwide. The business model will achieve management goals by consolidating the fragmented CBD industry via acquisitions. The Ticker symbol CBDW will provide market recognition of these goals and the company's business model. "It’s always been a critical component of trading on the public markets for companies to utilize a stock symbol that reinforces the mission of the company. We purposefully requested the ticker symbol "CBDW" because that ticker represents us as a business. Our core focus is on buying companies with great wellness products and brands that embody the benefits of CBD, and the ticker says all of that in just four letters." said Greg Lambrecht, CEO, and Chairman of 1606 Corp. 1606 Corp (OTC: CBDW) has signed a letter of intent (LOI) to purchase 51% of Brio Nutrition’s ( https://brionutrition.com / ), a profitable CBD development and distribution company. Brio Nutrition's has agreed to an LOI with 1606 Corp and filed for an audit on September 30th, 2022, which is still pending. Upon completion of the audit, a combination of stock and cash, totaling USD 600,000.00, will be transferred, and the transaction will be complete. Brio Nutrition Revenue (unaudited) 2021 $763,079 2020 $1,116,336 "Brio Nutrition's is the first of many acquisitions we intend on closing this year. The CBD market is quite fragmented and growing so we're on a mission to consolidate the industry by purchasing companies with strong product brands and established distribution. We'll use these accumulated outlets to cross-pollinate our product line. It's going to be the key to our success" Said Greg Lambrecht CEO of 1606 Corp DBA CBD Inc. About Brio Nutrition; Brio Nutrition is a premium CBD product developer, supplier, and wellness company focused on providing the highest quality hemp derivatives and formulations for people and pets. Brio Nutrition develops and supplies CBD gummies, topicals, capsules, topicals and oils to assist.in treating pain, anxiety, sleep performance, and depression for all those in need. The products developed and distributed by Brio provide holistic solutions designed to ensure a higher quality of life for all living beings. About 1606 Corporation Management; Greg Lambrecht has successfully taken three companies public. He is starting with premium cigars International which went to the NASDAQ in 1997. Again in 2011, Mr. Lambrecht took Singlepoint public on the OTC Markets. Singlepoint is pursuing a move up the NASDAQ as well. He will take the knowledge and expertise learned in both these endeavors into the new public entity 1606 Corp. About 1606 Corp; In April 2021, 1606 Corp. was spun off from Singlepoint Inc. (OTCQB: SING).1606 has been able to develop smokable hemp brands to add to 1606 original, including Truz and CBD Singlez ( www.1606hemp.com ) The company intends to acquire Companies in the CBD, including brands, distribution, retail outlets, and manufacturing. 1606 Corp. was awarded the ticker symbol CBDW on January 12th, 2022. Industry Information; The Cannabidiol (CBD) market accounted for USD 12.8 billion in 2021 and is estimated to grow with a 21.7% CAGR between 2022 and 2028, according to Grand view research (link). The global cannabidiol (CBD) market size was valued at $5.18 billion in 2021 and is expected to expand, at a compounded annual growth rate (CAGR) of 16.8% from 2022 to 2030. Cannabidiol (CBD) is a chemical compound that is found in the cannabis Sativa plant, and is extracted from hemp or cannabis, generally from hemp due to its naturally high cannabidiol (CBD) content.. Forward-Looking Statements This press release contains statements that constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements appear in a number of places in this release and include all statements that are not statements of historical fact regarding the intent, belief, or current expectations of 1606 Corp (the "Company"), its directors, or its officers with respect to, among other things: (i) financing plans; (ii) trends affecting its financial condition or results of operations; (iii) growth strategy and operating strategy. The words "may," "would," "will," "expect," "estimate," "can," "believe," "potential" and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company's ability to control, and actual results may differ materially from those projected in the forward-looking statements as a result of various factors. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties, and other factors, which are, in some cases, beyond the Company's control and which could, and likely will materially affect actual results, levels of activity, performance, or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company's expectations include, but are not limited to, those factors that are disclosed under the heading "Risk Factors" and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Contact: Greg Lambrecht greg@1606corp.com CBD.inc Austen Lambrecht austen@1606corp.com CBD.inc 888-223-9510 Company Websites; www.1606hemp.com www.CBD.Inc Contact Details Greg Lambrecht greg@1606corp.com Austen Lambrecht austen@1606corp.com

January 26, 2023 08:00 AM Eastern Standard Time

Spectral MD "very excited" about 2023

Spectral MD Holdings Ltd

Spectral MD Holdings Ltd (AIM:SMD) chief operating officer Niko Pagoulatos speaks to Proactive's Thomas Warner about his plans for the company during 2023. He reveals more details about the timeline for the DeepView Wound Imaging System and explains what milestones investors can expect, adding that he is "very excited" about what the year has in store. Contact Details Proactive Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

January 26, 2023 03:00 AM Eastern Standard Time

Video

Oxford Cannabinoid Technologies with "lots to look forward to" after interims

Oxford Cannabinoid Technologies Holdings PLC

Oxford Cannabinoid Technologies Holdings PLC (LSE:OCTP, OTCQB:OCTHF) CEO Clarissa Sowemimo-Coker speaks to Proactive's Thomas Warner following the release of interim results for the six months ending 31st October 2022. Sowemimo-Coker looks ahead to what investors can expect during the first half, saying that there is "plenty to look forward to." She also reveals details of the current state of the company's finances. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

January 26, 2023 03:00 AM Eastern Standard Time

Video

1 ... 140 141 142 143 144 ... 248